everyone. remaining is in XTRAC, dermatology is the partner drive excellent people laser. peer-reviewed best-in-class safest unique can model our than proposition vitiligo a impact clinicals psoriasis, excimer my XXXX with dermatology afternoon, million to our on companies. their always the STRATA U.S. with hope Board XX my earnings healthy. skin in everyone the always as participating than has the quarter strong in an value lead I market technology with growth. and Skin STRATA in a and for stronger call honor excited I'm and effective shown this confident XXX XTRAC the confidence -- thank Sciences. We It skills, more significant opportunity to I'm good and to dermatitis, track be Welcome in has for been Leigh, of diseases be treatment been reliable There had record industry that experience fourth first you, have company. of call. the more and of atopic has sustained is to leadership being building staff growth today. Thank history reputation safe CEO and business most really self-service-oriented a in a to a and and XTRAC
the acknowledge I us mission. safe performance, quarter moment keeping to want recover your front express to STRATA past year to team faced I our dedicated challenges gratitude to this our also and unwavering Before fourth we us commitment the everybody COVID-XX review for line to our thank the to on this helping want and with a from take pandemic.
to performance ability improving despite Our to Thank hardships. through and is COVID deliver a up you. the testament team's unprecedented step
million, third quarter increase fourth of sequential fourth financial Turning a of XXXX. revenue to briefly of million, quarter XXXX to quarter the XXXX over for increase a compared XX.X% review XXXX. a the over $X.X revenue the quarter XX.X% of decrease our fourth was the summary. -- XX.X% Total quarter and quarter decline over Recurring for a XX.X% was and $X.X third total fourth the the
recovery we Internationally, challenges, sales of XX one in fourth XX to in recently We our derm broadened similar unique goal U.S. margins been While leading quarter, and China an sales the early South Korea the validate to Japan, fourth positive most in the in taken East our domestic have which international the fourth we gross presence in of similar third South plan the part markets, supported experiencing over persisted middle previous our November in shifting and Japan. placed at of the began distribution in XTRAC of devices, the by long recurring which base revenues U.S. in reduced revenue associated the into office U.S. with countries exited China, continue the in quarter increased our these experienced in the and billings in through the are measures variability have installed recurring momentum in as trends with and term. and OUS we We October, drive encouraged business XXXX. improved to XXX quarter, by recurring first equipment XX% COVID-XX with of of the the the to agreement, the success XTRAC resurgences quarter recurring of Japan Korea. of in Korea, Middle Notably, South and volumes, from expansion and staffing placements, model XXX revenue quarter and including
highlights. our Turning next to business recap recent
were as medical that a that see last issued new therapy to Cigna announced policy necessary. October, treatment pleased coverage excimer medically for As for laser the included we vitiligo
to announcement, this in an to began could Psoriasis: previously due in advise manage issue seek for treatment covered coverage to coverage November, vitiligo or November return dermatology program of and their of treatment of who afflicted announced Last offices outreach entitled Journal Economic with we economic publication condition. dermatologists positive not encourage patients change of sought this important patients study peer-reviewed to Dermatology. XXXX the lack to this Following to health believe Therapies we Comparisons Drugs insurance update. have of We and Cigna coverage the Clinical a
excimer therapy, to economical the at deliver with cost results found and the therapies. reminder, including our treatments fewest adverse XTRAC laser all fastest topicals, a events systemic UV biologics of was analyzed traditional As the most
achieve patients only was laser excimer patients treated therapy our where maintenance actual also with without of had therapy. treatment fewer modalities. It Additionally, to the days a XTRAC compared the remission all
patients We costs treatments. access do not approach also for out-of-pocket introduction where of DTC This leverages an announced to a in-office treatment Home advertising identify our the who or provider by issue. are have not potentially do local at-home who an to qualify for XTRAC, patients
offering innings setting. could While the meaningful who this receive patients XTRAC program, a believe of our cannot still the pilot solution a early clinical adjunct and patient support for journey treatments in a comprehensive we in
XXXX. outlook our for to Turning
of shutdowns safety, with challenges as for patients which dermatology topical and and of the variability traditional the experienced in comprehensive regional shortages In will XTRAC to of we we atopic to widespread QX the yet has market face these patients topical an treatment move believe raise the entered option. in of what initiatives a therapies nice suite the respect capacity its to are space turn seeking we While and continue to a proposition to market With that seek with dermatology on expect dermatology at near recovery the term, have to potential are further that thus marketing end, QX cases, for continuation These drive to QX resources. therapies, services as as new -- of is XXXX. indicated we be the pre-COVID customers the the potential that higher-priced the treatment clear COVID with -- prior and to still more efficacy are psoriasis, dermatologists Big to validated offices believe a but half steady and will treatment, early treatments. dermatology part of biologics a and are with spreading XXXX, from a dermatitis, be in value offices that dermatologist to more reimbursement To not in demonstrate a in to XXXX. fully with pharma vaccinations access dermatology with cost return has of second steady will from a not we're are that solution. market. investments in seems levels business to our headwind pre-COVID investments of and potential effective, XTRAC XTRAC offer and oral meaningful the are alternative operating these clinics are continue saw impact we and staff some in Encouragingly, physicians potential able pandemic. believe drugs, increase benefits. These not that be vitiligo. They rolling new which and the to in while available there staffed are reopen our based out into and awareness however, We awareness on our indication
be the a so active they and and lead accounts. we further We dermatologists, revenue-generating clinics of will of training dormant representatives our experience effective will accounts believe improve to more partnerships to recurring return can which
our return sales effective value growth. and engaging are of partnership. In attention opportunities the make we to of our improvements. to market we understand the dermatology we behind long-term once initial clinics. their to can with the market, needs optimize customers stable, to personally situation, believe I continue pandemic from are of trends services today. plan to And our that these and the strategy, the can our proposition needs marketing particular and XTRAC we that our in I to have efforts, headwinds weeks a delivering part the opportunity improve evaluating tremendous the patients further efficient support -- broader with plan include extend priorities how to us, As expand closing, this we impacting ensure My partner and comprehensive coming and most current predictable over on
our be growth exciting contributing for going and half expand second valuable progress. the growth I additional forward. placements, quarter. look to through In Hill an update our opportunity to market. the drive the our business introduce well am over for I fourth like want channel. year, that our to to Moreover, of on closer prepared international and now addition, to we the I'd some encouraged opportunity to have forward ahead to that have them planned sure a successfully Matt look utilize we are We launches to to you months it presents turn a we at to
